Fig. 1.

WY14,643 decreases proteinuria in anti-glomerular basement membrane disease (AGBMD). AGBMD was induced in C57BL/6 mice. Three days prior to immunization and throughout the time–course of the study mice were treated with control or WY14,643 (0·05% in the food). (a) Throughout the course of the disease mean group urine albumin/creatinine ratios were lower in the WY14,643-treated mice. (P < 0·05, 2 by 18 analysis of variance with repeated measures and tests for linear and quadratic trends). (b) Mice that developed albumin/creatinine ratios of ≥ 3 were considered to have high-grade proteinuria. Accordingly, proteinuria-free survival is significantly higher in the WY14,643-treated mice when compared with the control-fed mice. P < 0·01, Kaplan–Meier survival analysis.